WO2020165473A1 - Formulación o adhesivo tisular obtenido de una composición sanguínea que contiene plaquetas, y método de preparación de dicha formulación - Google Patents
Formulación o adhesivo tisular obtenido de una composición sanguínea que contiene plaquetas, y método de preparación de dicha formulación Download PDFInfo
- Publication number
- WO2020165473A1 WO2020165473A1 PCT/ES2020/070048 ES2020070048W WO2020165473A1 WO 2020165473 A1 WO2020165473 A1 WO 2020165473A1 ES 2020070048 W ES2020070048 W ES 2020070048W WO 2020165473 A1 WO2020165473 A1 WO 2020165473A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- prp
- platelets
- plasma
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- the invention relates to a formulation with desirable biological or medical properties, obtained from an initial blood composition containing platelets.
- the invention also relates to a method of preparing said formulation.
- the formulation serves as a tissue adhesive.
- compositions from human or animal blood where the blood is processed in such a way as to obtain a plasma rich in platelets (PRP) and / or a plasma rich in growth factors that they have useful biological and medical properties.
- PRP plasma rich in platelets
- Said PRP or plasma rich in growth factors have been used successfully in ex vivo applications, for example as a cell culture medium, and in vivo, for example to carry out a bone regeneration process in a patient or to treat a patient for a joint ailment through infiltrations.
- the technology for preparing PRP formulations and plasma rich in growth factors has evolved towards the preparation of autologous compositions, that is, obtained from the patient's own blood. Examples of this type of compositions and preparation methods can be found in patents US6569204 and ES2221770.
- compositions consisting of platelet-rich fibrin (PRF), obtained from blood, are also known.
- PRF platelet-rich fibrin
- fibrin can be autologous or heterologous.
- plasma which is liquid, fibrin has a solid or semi-solid consistency.
- fibrin gel or fibrin mesh An example of fibrin is known as fibrin gel or fibrin mesh, which is a formulation whose semi-solid consistency is very convenient for certain applications.
- the fibrin gel or mesh preparation procedure generally begins with a first phase in which a PRP or growth factor-rich plasma is obtained by an applicable method, for example by centrifuging blood drawn from a patient until the blood separates. in several fractions, and extracting the upper fraction, that is the fraction of platelet rich plasma (PRP) or plasma rich in growth factors. Subsequently, the platelets contained in the PRP or plasma rich in growth factors are activated (activation being understood as the action of causing the platelets to release certain growth factors contained within), for example by adding calcium chloride.
- PRP platelet rich plasma
- fibrin gel also called fibrin gel or mesh for its semi-solid consistency, like a kind of biological sponge.
- This procedure is usually performed to obtain a fibrin gel from blood modified with an anticoagulant, such as sodium citrate.
- an anticoagulant such as sodium citrate.
- blood can also be processed without mixing it previously with anticoagulant; In this case, by centrifuging the blood it is possible to separate the plasma from the red blood cells and, at the same time, to obtain the fibrin gel without the need to add calcium chloride or another platelet activator.
- fibrin gel or mesh application are: forming a biological scaffold to fill bone defects; be applied on wounds or lesions for the progressive release of growth factors; be used as a matrix for stem cell culture; be used as a membrane to close defects or ulcers; be used in the manufacture of tissues, which is known as tissue engineering, where in addition to cells and growth factors it is especially important to have a matrix or scaffold where the cells can grow.
- tissue engineering where in addition to cells and growth factors it is especially important to have a matrix or scaffold where the cells can grow.
- platelet-rich preparations PRP, plasma rich in growth factors, PRF
- PRF platelet-rich preparations
- PRF plasma rich in growth factors
- the object of the invention is a formulation with desirable biological or medical properties, which comprises or is derived from an initial blood composition (of human or animal origin; autologous, homologous or heterologous), rich in platelets and / or growth factors and which comprises proteins from the initial blood composition itself, with the particularity that the formulation presents an increased adhesiveness.
- This formulation can be autologous (it is prepared and applied to the same donor), homologous (the donor and the recipient are of the same species) or heterologous (the donor and recipient are of different species and could be classified as a “sealant of fibrin ”(using a terminology analogous to that used to refer to the application of fibrin preparations to seal) due to its increased adhesiveness and accelerated coagulation.
- the composition presents a new morphological and biomechanical configuration compared to the rest of senators of fibrin, blood compositions rich in platelets and / or growth factors, and the like known in the state of the art.
- the formulation according to the invention is biocompatible, biodegradable and exhibits the desirable biological or medical properties provided by the presence of platelets or growth factors.
- the formulation exhibits increased tissue adhesiveness and is obtained in short times.
- the formulation according to the invention is therefore an advantageous alternative to conventional fibrin sealant, due to the fact that the formulation is autologous, adhesive and is obtained in a short time without the addition of chemicals.
- the formulation exhibits good compressive adhesiveness, similar to or better than the conventional allogeneic fibrin sealant Tisseel® and PRP (commonly used as a sealant), and adequately supports the resistance that a tissue can exert; therefore, the formulation is very suitable for use as a fibrin sealant. In addition, it is injectable.
- Another object of the invention is a method of preparing the above formulation, wherein said method comprises the steps of: having an initial blood composition rich in platelets and / or growth factors whose base formulation can vary; heating the blood composition having a temperature of 40 to 55 Q C; centrifuge the initial blood composition for at least 1 minute; reduce the volume of the initial composition.
- This method of the invention also comprises the addition of a platelet activating substance and the formation of fibrin to obtain a blood composition rich in platelets and / or growth factors in gel form.
- FIG. 1 shows the coagulation time of different examples of formulations according to the invention.
- FIG. 3 shows the effect of the activator and platelets on the clotting time of the formulations according to the invention.
- FIG. 6 shows the efficacy as a tissue adhesive of different examples of formulations according to the invention compared to the commercial sealant Tisseel® as a tissue adhesive.
- Said formulation comprises or is derived from an initial blood composition containing platelets.
- This composition is adhesive due to heat treatment and formation of a fibrin clot.
- the sealant prepared according to this invention has been found to have a tissue adhesiveness similar to the Tisseel® fibrin sealant and better than the adhesiveness of a conventional platelet-rich fibrin or platelet-rich plasma.
- the initial blood composition can be, for example, a platelet-rich blood plasma, that is, a plasma with a high concentration of platelets.
- Said plasma has generally been obtained through the technique of centrifuging blood (to separate it into a fraction of a fraction of red blood cells, a fraction of white blood cells and a fraction of platelet-rich plasma (PRP)) and separating all or part of the fraction of platelet rich plasma (PRP).
- the initial blood composition may or may not contain leukocytes.
- the initial blood composition For the activation of the initial blood composition one or more of: calcium chloride, thrombin, sodium gluconate, collagen, supernatant (a liquid substance that appears on the clot when coagulation of a platelet-rich plasma (PRP) is caused ) and its subsequent retraction), supernatant of a blood plasma rich in growth factors, or any other agent that acts by activating platelets and inducing fibrin formation in such a way that the platelets have released certain growth factors from within.
- PRP platelet-rich plasma
- a method of preparing a formulation with desirable biological or medical properties comprises the steps of: a) having an initial blood composition rich in platelets and / or growth factors with or without anticoagulant, which is preferably a platelet-rich plasma with or without leukocytes, or a growth factor-rich plasma with or without leukocytes. b) Raise the temperature of the initial composition at a temperature of 40 to 55 Q C. c) Centrifuge the initial blood composition during at the least 1 minute. d) Remove at least part of the plasma fraction obtained as a result of centrifugation. e) Activate the blood composition that remains after removing at least part of the plasma fraction as indicated in step d).
- Activation can be performed, for example, by adding calcium chloride, thrombin, a combination of calcium chloride and thrombin, sodium gluconate, collagen, supernatant (a substantial liquid that appears on the clot when coagulation of a rich plasma is caused platelets (PRP) and its subsequent retraction), supernatant of a blood plasma rich in growth factors and / or any other platelet activating agent.
- platelets are activated and fibrin formation is induced so that platelets release from their interior certain growth factors.
- the above method produces a precipitation of protein substances without the denaturation of fibrinogen as evidenced by the obtaining of a fibrin clot after activation.
- the concentration of these protein substances is increased.
- the method produces a remarkable acceleration in the coagulation of the blood composition and in its adhesion strength.
- new biocompatible and biodegradable formulations are achieved, with two main advantages: a short coagulation time and a higher adhesiveness, which makes this formulation can be applied as an adhesive or fibrin sealant.
- the temperature of the initial blood composition is increased to a temperature in the range of 40 to 53 Q C.
- the initial blood composition rich in platelets and / or growth factors can be of human or animal origin.
- it can be autologous (belonging to a patient whom it is desired to treat later with the final formulation), homologous (belonging to a member of the same species as the patient, patients, cells or other biological entity to be treated or processed with the final formulation) or heterologous (belonging to a member of a different species than the patient, patients, cells, or other biological entity to be treated or processed with the final formulation).
- the initial blood composition may optionally incorporate one or more additional substances, added prior to the claimed heat treatment.
- additional substances can be:
- bioactive agents selected from proteins, peptides, nucleic acids, polysaccharides, lipids, non-protein organic substances and inorganic substances;
- biodegradable polymers selected from: acid hyaluronic, hyaluronate salts, chondroitin 4 sulfate, chondroitin 6 sulfate, dextran, silica gel, alginate, hydroxypropylmethylcellulose, chitin derivatives, preferably chitosan, xanthan gum, agarose; polyethylene glycol (PEG), polyhydroxyethylene methacrylate (HEMA), synthetic or natural proteins, collagens;
- PEG polyethylene glycol
- HEMA polyhydroxyethylene methacrylate
- organic polymers selected from the group of polycarpolactone, polyglycolic, polylactic, and their co-polymers;
- antibiotics antibiotics, antimicrobials, anticancer agents, analgesics, growth factors, hormones;
- inorganic components selected from the group of calcium salts, magnesium salts, and / or strontium salts.
- the invention also contemplates that any of the above substances can be added to the formulation after the heat treatment has been carried out.
- the formulation according to the invention contemplates various embodiments in which the formulation may comprise, in addition to the technical aspects claimed, other compounds, components, molecules, etc. that are convenient for the specific application for which the formulation is intended. Furthermore, it is possible to perform additional steps on the formulation produced according to the method described in this invention that include desiccates to increase its versatility. That is, prior to its activation (activation of platelets and formation of fibrin), the formulation according to the invention can be dried (dry heat) or lyophilized.
- This formulation can be subsequently rehydrated by different alternatives such as adding a saline solution, a plasma rich in platelets, a supernatant of a plasma rich in platelets, a plasma rich in growth factors, a supernatant of a plasma rich in growth factors, or any other liquid substance.
- Example 1 The starting point is a sample of 9 tubes (9ml) that hermetically contain blood drawn from a patient.
- the tubes are centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature. As a consequence of centrifugation, the blood contained in each tube is divided into several fractions.
- the upper fraction, or platelet-rich plasma (PRP) fraction is extracted into a white tube, obtaining a total of 36 ml of plasma.
- the plasma is distributed into 6 tubes, each tube containing 6 ml of plasma. Then, the temperature each of the six tubes is raised to 37.55, 45.95, 51, 05, 52.4, 53.9 and 55.35 Q C, respectively.
- PRP platelet-rich plasma
- the 6 tubes are centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature, producing the precipitation of platelets and new protein substances.
- the upper half of the plasma is removed.
- the precipitate is resuspended in the plasma that has remained in the tube.
- the formulations in the 6 tubes are activated by adding a PRP supernatant (333mI) and 20 ml of calcium for each 1 ml of formulation, which initiates the formation of fibrin in the formulations.
- a PRP supernatant 333mI
- 20 ml of calcium for each 1 ml of formulation, which initiates the formation of fibrin in the formulations.
- Clotting time (the time it takes for the blood composition to change its state from liquid to gel) due to fibrin formation has been measured.
- Figure 1 shows the ability of the method of the invention to accelerate clotting time.
- the clotting time of a conventional PRP activated in the same way as the previous formulations according to the invention (that is, with PRP supernatant (333mI) and 20 ml of calcium per 1 ml) has been 4.5 minutes.
- the formulations according to the invention have lower or accelerated coagulation times with respect to said conventional PRP. Said acceleration of Coagulation is higher for the temperature of 51 05 Q C, followed by 52.4 and 53.9 temperatures Q C. No coagulum obtained stable when the temperature is 55.3 Q C.
- Example 2
- the starting point is a sample of 9 tubes (9ml) that hermetically contain blood drawn from a patient.
- the blood is centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature.
- the upper fraction, or platelet-rich plasma (PRP) fraction is extracted into a white tube, obtaining a total of 36 ml of plasma.
- the plasma is distributed into 6 tubes, each tube containing 6 ml of plasma. Thereafter, the temperature of each of the tubes 37,55, 45,95, 51, 05, 52.4, 53.9 and 55.35 Q C respectively rises.
- the formulations in the 6 tubes are activated by adding a PRP supernatant (333mI) and 20 ml of calcium for each 1 ml of formulation, which initiates the formation of fibrin in the formulations.
- a PRP supernatant 333mI
- 20 ml of calcium for each 1 ml of formulation, which initiates the formation of fibrin in the formulations.
- the starting point is a sample of 9 tubes (9ml) that hermetically contain blood drawn from a patient.
- the tubes are centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature. As a consequence of centrifugation, the blood contained in each tube is divided into several fractions.
- the upper fraction, or platelet-rich plasma (PRP) fraction is extracted into a white tube, obtaining a total of 36 ml of plasma.
- the plasma is distributed into 6 tubes, each tube containing 6 ml of plasma. Samples are processed according to the following:
- Control-activator sample PRP that is activated with PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- PRP that is centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature. 2/3 of the initial volume is removed and the platelet precipitate is resuspended in the remaining 1/3 of the initial volume. It is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the formulation is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the formulation is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the platelet and protein precipitate is resuspended in the total initial volume.
- the formulation is activated with supernatant of PRP (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- - Formulation sample 4 Platelets are removed from PRP by filtration with filters with a pore size of 20 ml. The temperature of the PRP is then up to 51 Q C. then centrifuged at a speed of 580 g for 8 minutes and time room temperature. 2/3 of the initial volume is removed and the platelet and protein precipitate is resuspended in the remaining 1/3 of the initial volume. The formulation is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the results of the clotting time in Figure 3 indicate that: the use of the activator thrombin (PRP supernatant) + calcium, used in the control-activator, control-method and formulations 1 -4, accelerates the coagulation of PRP with respect to the use only calcium ions (control sample). Also, a second centrifugation of the PRP before activation (control-method and formulations 1-4) accelerates coagulation even more, possibly due to the increase in platelet concentration by removing part of the initial volume. However, the method according to the invention accelerates coagulation independently of the platelet concentration as shown by the results of formulation 3 (without increase in platelet concentration) and formulation 4 (without platelets). The shorter clotting times were those corresponding to formulations 1 and 2. Thus, the clotting time indicates the novelty and effectiveness of the method of the invention to accelerate the clotting process.
- the starting point is a sample of 9 tubes (9ml) that hermetically contain blood drawn from a patient.
- the tubes are centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature. As a consequence of centrifugation, the blood contained in each tube is divided into several fractions.
- the upper fraction, or platelet-rich plasma (PRP) fraction is extracted into a white tube, obtaining a total of 36 ml of plasma.
- the plasma is distributed into 6 tubes, each tube containing 6 ml of plasma. Samples are processed according to the following:
- Control-activator sample PRP that is activated with PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- PRP that is centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature. 2/3 of the initial volume is removed and the platelet precipitate is resuspended in the remaining 1/3 of the initial volume. It is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the formulation is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the platelet and protein precipitate is resuspended in the total initial volume.
- the formulation is activated with supernatant of PRP (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- - Formulation sample 4 Platelets are removed from PRP by filtration with filters with a pore size of 20 ml. The temperature of the PRP is then up to 51 Q C. then centrifuged at a speed of 580 g for 8 minutes and time room temperature. 2/3 of the initial volume is removed and the platelet and protein precipitate is resuspended in the remaining 1/3 of the initial volume. The formulation is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the starting point is a sample of 8 tubes (9ml) that hermetically contain blood drawn from a patient.
- the tubes are centrifuged at a speed of 580 g, for a time of 8 minutes and room temperature.
- the upper fraction, or platelet-rich plasma (PRP) fraction is extracted into a white tube, obtaining a total of 30 ml of plasma.
- the plasma is distributed into 5 tubes, each tube containing 6 ml of plasma. Samples are processed according to the following:
- Control-activator sample PRP that is activated with PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the formulation is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the formulation is activated with the following activator / formulation volume ratios:
- Tisseel® Sample A commercial Tisseel® adhesive and sealant (Baxter S. L., Valencia, Spain) has been purchased and used according to the manufacturer's instructions.
- the starting point is a sample of 7 tubes (9ml) that hermetically contain blood drawn from a patient.
- the tubes are centrifuged at a speed of 580 g, for a time of 8 minutes and at room temperature.
- the blood contained in each tube is divided into several fractions.
- the upper fraction, or platelet-rich plasma (PRP) fraction is extracted into a blank tube, obtaining a total of 24 ml of plasma.
- the plasma is divided into 4 tubes, each tube containing 6 ml of plasma. Samples are processed according to the following:
- Control-activator sample PRP that is activated with PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- the formulation is activated with a PRP supernatant (333 ml) and 20 ml of 10% calcium chloride for each 1 ml of PRP.
- Tisseel® Sample A commercial Tisseel® adhesive and sealant (Baxter S. L, Valencia, Spain) has been purchased and used according to the manufacturer's instructions.
- Biological samples of pig skin have been prepared. The skin samples have been glued to a support using a universal adhesive. Then two skin specimens have been glued with the samples described above. The adhesion strength of the formulation was then measured using gram weights and hanging them on the support of a skin specimen.
- Figure 6 shows the novelty and effectiveness of the invention in improving adhesion strength and that adhesion capacity can be further increased by optimizing the volume of activator added (Formulation 2B).
- the results also indicate that the adhesion force of the formulation according to the present invention (Formulation 2 B) is comparable with the adhesion force of the commercial sealant of the Tisseel® brand.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20708156.3A EP3925613A1 (en) | 2019-02-11 | 2020-01-22 | Tissue formulation or adhesive obtained from a blood composition containing platelets, and method of preparing such formulation |
MX2021008826A MX2021008826A (es) | 2019-02-11 | 2020-01-22 | Formulación o adhesivo tisular obtenida de una composición sanguínea que contiene plaquetas, y método de preparación de dicha formulación. |
CA3129633A CA3129633A1 (en) | 2019-02-11 | 2020-01-22 | Tissular formulation or adhesive obtained from a blood composition containing platelets, and method for preparation of said formulation |
JP2021546794A JP7291972B2 (ja) | 2019-02-11 | 2020-01-22 | 血小板を含有する血液組成物から得られる組織製剤又は接着剤、及びそのような製剤を調製する方法 |
CONC2021/0010335A CO2021010335A2 (es) | 2019-02-11 | 2021-08-05 | Formulación o adhesivo tisular obtenido de una composición sanguínea que contiene plaquetas, y método de preparación de dicha formulación |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201930106A ES2778798B2 (es) | 2019-02-11 | 2019-02-11 | Formulacion o adhesivo tisular obtenida de una composicion sanguinea que contiene plaquetas, y metodo de preparacion de dicha formulacion |
ESP201930106 | 2019-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020165473A1 true WO2020165473A1 (es) | 2020-08-20 |
Family
ID=69726605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2020/070048 WO2020165473A1 (es) | 2019-02-11 | 2020-01-22 | Formulación o adhesivo tisular obtenido de una composición sanguínea que contiene plaquetas, y método de preparación de dicha formulación |
Country Status (10)
Country | Link |
---|---|
US (1) | US11744917B2 (es) |
EP (1) | EP3925613A1 (es) |
JP (1) | JP7291972B2 (es) |
AR (1) | AR118039A1 (es) |
CA (1) | CA3129633A1 (es) |
CO (1) | CO2021010335A2 (es) |
ES (1) | ES2778798B2 (es) |
MX (1) | MX2021008826A (es) |
TW (1) | TW202045191A (es) |
WO (1) | WO2020165473A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114058675B (zh) * | 2020-08-04 | 2022-11-15 | 深圳市帝迈生物技术有限公司 | 稳定剂、凝血酶时间测试试剂及其制备方法、试剂盒 |
CN115463249A (zh) * | 2022-08-11 | 2022-12-13 | 中南大学湘雅医院 | 一种负载富血小板血浆水凝胶及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569204B1 (en) | 1999-01-26 | 2003-05-27 | Eduardo Anitua Aldecoa | Bone tissue regenerating composition |
ES2221770A1 (es) | 2002-04-19 | 2005-01-01 | Eduardo Anitua Aldecoa | Metodo de preparacion de un compuesto para la regeneracion de tejidos. |
EP2740486A1 (en) * | 2011-07-29 | 2014-06-11 | Eduardo Anitua Aldecoa | Process for a growth factor containing composition from platelets |
US20150037430A1 (en) * | 2013-08-01 | 2015-02-05 | Biotechnology Institute, I Mas D, S.L. | Formulation of a blood composition that is rich in platelet and/or growth factors and contains gelled proteins, and a method for its preparation |
ES2633815A1 (es) * | 2016-03-23 | 2017-09-25 | Biotechnology Institute I Mas D, S.L. | Formulación de aplicación tópica, rica en plaquetas y/o factores de crecimiento y un método de preparación de la misma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010142784A2 (en) * | 2009-06-11 | 2010-12-16 | Universitat Autònoma De Barcelona | Use of gelled prp (platelet gel) for volumetric breast reconstruction |
-
2019
- 2019-02-11 ES ES201930106A patent/ES2778798B2/es active Active
-
2020
- 2020-01-22 EP EP20708156.3A patent/EP3925613A1/en active Pending
- 2020-01-22 CA CA3129633A patent/CA3129633A1/en active Pending
- 2020-01-22 MX MX2021008826A patent/MX2021008826A/es unknown
- 2020-01-22 WO PCT/ES2020/070048 patent/WO2020165473A1/es active Application Filing
- 2020-01-22 JP JP2021546794A patent/JP7291972B2/ja active Active
- 2020-02-05 TW TW109103431A patent/TW202045191A/zh unknown
- 2020-02-10 AR ARP200100346A patent/AR118039A1/es unknown
- 2020-02-11 US US16/787,190 patent/US11744917B2/en active Active
-
2021
- 2021-08-05 CO CONC2021/0010335A patent/CO2021010335A2/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569204B1 (en) | 1999-01-26 | 2003-05-27 | Eduardo Anitua Aldecoa | Bone tissue regenerating composition |
ES2221770A1 (es) | 2002-04-19 | 2005-01-01 | Eduardo Anitua Aldecoa | Metodo de preparacion de un compuesto para la regeneracion de tejidos. |
EP2740486A1 (en) * | 2011-07-29 | 2014-06-11 | Eduardo Anitua Aldecoa | Process for a growth factor containing composition from platelets |
US20150037430A1 (en) * | 2013-08-01 | 2015-02-05 | Biotechnology Institute, I Mas D, S.L. | Formulation of a blood composition that is rich in platelet and/or growth factors and contains gelled proteins, and a method for its preparation |
ES2633815A1 (es) * | 2016-03-23 | 2017-09-25 | Biotechnology Institute I Mas D, S.L. | Formulación de aplicación tópica, rica en plaquetas y/o factores de crecimiento y un método de preparación de la misma |
Also Published As
Publication number | Publication date |
---|---|
JP7291972B2 (ja) | 2023-06-16 |
US20200254138A1 (en) | 2020-08-13 |
CO2021010335A2 (es) | 2021-08-19 |
MX2021008826A (es) | 2023-03-02 |
CA3129633A1 (en) | 2020-08-20 |
ES2778798B2 (es) | 2021-10-13 |
TW202045191A (zh) | 2020-12-16 |
AR118039A1 (es) | 2021-09-15 |
EP3925613A1 (en) | 2021-12-22 |
US11744917B2 (en) | 2023-09-05 |
ES2778798A1 (es) | 2020-08-11 |
JP2022520776A (ja) | 2022-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6588499B2 (ja) | トロンビン血清の調製、その利用およびその調製機器 | |
ES2831708T3 (es) | Preparaciones de células para uso extemporáneo, útiles para cicatrización y rejuvenecimiento in vivo | |
ES2896338T3 (es) | Fracción de suero de fibrina rica en plaquetas | |
ES2778798B2 (es) | Formulacion o adhesivo tisular obtenida de una composicion sanguinea que contiene plaquetas, y metodo de preparacion de dicha formulacion | |
ES2755172T3 (es) | Formulación de una composición sanguínea rica en plaquetas y/o factores de crecimiento, con proteínas gelificada, y método de preparación de la misma | |
JP7223447B2 (ja) | 止血用組成物及びこれを含む容器 | |
JP2016514716A (ja) | 組織の再生および創傷の治療のための植え込み型製剤、それらの製剤化方法、および該植え込み型製剤を用いる患者の治療方法 | |
Vozel et al. | Treatment with platelet-and extracellular vesicle-rich plasma in otorhinolaryngology-a review and future perspectives | |
ES2221770B2 (es) | Metodo de preparacion de un compuesto para la regeneracion de tejidos. | |
JP6877360B2 (ja) | 止血組成物 | |
Goczyńska et al. | Fibrin glues—the current state of knowledge | |
RU2820448C2 (ru) | Тканевая композиция или адгезив, полученные из композиции крови, содержащей тромбоциты, и способ приготовления указанной композиции | |
US11311643B2 (en) | Fibrin and/or dialdehyde starch hydrolysate materials, and preparation and use thereof | |
ES2846923T3 (es) | Composición para regenerar tejido óseo, procedimiento de preparación y uso de la misma | |
Issa et al. | PRP: a possibility in regenerative therapy | |
ES2782723B2 (es) | Procedimiento para obtencion y conservacion de factores de crecimiento de alta pureza y sus usos | |
Mustafa et al. | Application of platelet-rich plasma (PRP) in corneal lesions-a review. | |
WO2020016476A1 (es) | Material inyectable para la regeneración del cartílago articular | |
Grimaldi et al. | Biotechnological Approaches to Hemostasis and Molecular Mechanisms of Wound Healing | |
UA113094C2 (xx) | Спосіб одержання аутологічного фібринового гелю для стимуляції регенерації кісткових і м'яких тканин і зниження інтенсивності запальних процесів | |
RU2224540C1 (ru) | Биологический адгезивный клей | |
Li et al. | Effects of sustained release Platelet-rich plasma on bone healing in critical-size defect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20708156 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3129633 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021546794 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021123681 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2020708156 Country of ref document: EP Effective date: 20210913 |